Business
Aileron Therapeutics Announces Plans to Release Interim Results from its Phase 1b/2 Myelopreservation Study in Mid-2020
Presentation of interim results from the dose-optimization part of the Phase 1b myelopreservation study - - - Final data readout from Phase 1b for both dose
About this update from Rein Therapeutics, Inc.
[{"type":"text","content":"Presentation of interim results from the dose-optimization part of the Phase 1b myelopreservation study - - - Final data readout from Phase 1b for both dose optimization and schedule optimization in Q4 2020- - -Updated corporate presentation available on the Company’s website\n WATERTOWN, Mass., April 22, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today announced plans to report interim results from their Phase 1b/2 clinical trial of ALRN-6924 in small cell lung cancer (SCLC). In this trial, ALRN-6924 is being evaluated as an agent to protect cancer patients against chemotherapy-induced toxicity, a concept known as myelopreservation or chemoprotection. “We are pleased with the continued progress of the dose-optimization portion of our Phase 1b clinical trial in which we treat small cell lung cancer patients with ALRN-6924 twenty-four hours before topotecan, a standard chemotherapy. Emerging data from the trial puts us on track to report interim results in mid-2020, and the final data readout in the fourth quarter of 2020,” said Dr. Manuel Aivado, President and CEO of Aileron Therapeutics. “Our goal for this interim data will be to further support our belief that ALRN-6924 has a protective effect against severe chemotherapy-induced anemia and thrombocytopenia.” The Company is currently conducting a Phase 1b/2 trial of ALRN-6924 in patients with SCLC to identify a dose and schedule of ALRN-6924 administration to reduce severe anemia and thrombocytopenia resulting from topotecan. In this trial, topotecan is administered daily on days 1 through 5 of every 21-day treatment cycle. ALRN-6924 is administered 24 hours before each dose of topotecan (on days 0 through 4 every 21 days), respectively. The Company currently plans to report final data from the Phase 1b portion of the trial in the fourth quarter of 2020. Those results will determine a recommended ALRN-6924 dose and schedule for subsequent studies. In addition, the Company has posted an updated investor presentation on the Investors & Media section of its website (click here). About ALRN-6924ALRN-6924 is a first-in-class dual MDM2/MDMX inhibitor that is currently being evaluated in a Phase 1b/2 clinical trial to evaluate ALRN-6924 as a chemoprotective agent to protect against chemotherapy-related toxicities. About AileronAileron is a clinical-stage biopharmaceut...